Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AGR Tablet (Rupatadine) in Perennial Allergic Rhinitis
NCT01982916Phase 3Completed
- Sponsor
- Ahn-Gook Pharmaceutical Co., Ltd.
- Start
- Dec 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rupatadine in perennial allergic rhinitis (PAR) (3 arms), sponsored by Ahn-Gook Pharmaceutical Co., Ltd. Primary endpoint: Change of 4 Nasal Total Symptoms Score from baseline at 4 weeks. Started Dec 2013; status: completed.
02
Drugs
rupatadine
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT01982916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01982916.